# Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older

> **NCT01949090** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 363 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Investigational H7N1 vaccine GSK2789869A
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT01949090
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-25
- **Primary completion:** 2013-12-04
- **Final completion:** 2014-10-23
- **Target enrollment:** 363 (ACTUAL)
- **Last updated:** 2017-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01949090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01949090, "Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01949090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*